Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jul;42(4):211-8.
doi: 10.1159/000435872. Epub 2015 Jul 1.

Standardization of NAT for Blood-Borne Pathogens

Affiliations
Review

Standardization of NAT for Blood-Borne Pathogens

Sally A Baylis et al. Transfus Med Hemother. 2015 Jul.

Abstract

Assays based on nucleic acid amplification technology (NAT) are increasingly used for screening of blood and for diagnosis or monitoring of patients. Both regulatory requirements for blood screening and international recommendations for the treatment of patients are based on common reference materials available globally for the standardization of NAT assays. World Health Organization International Standards (WHO ISs) and International Reference Panels (WHO IRPs) are primary reference materials. The characterization and manufacture of WHO reference materials as well as their evaluation is performed on behalf of the WHO by collaborating centers; their establishment is decided upon by the WHO Expert Committee on Biological Standardization (ECBS). The potency of the first WHO IS is defined by the 'international unit' (IU) which should be maintained upon replacement of the IS. The IU, unlike copy number or genome equivalent, is defined by the IS with a physical existence, is available worldwide, and allows traceability and comparability of results. The anticipated use of WHO ISs is the calibration of secondary standards or the validation of essential assay features, e.g. limit of detection.

Keywords: IVD; International unit; NAT; Standardization; WHO standards.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Paul-Ehrlich-Institut Stufenplan: Bekanntmachung über die Ergebnisse des Stufenplanverfahrens zur Verminderung des Risikos von Hepatitis B-, Hepatitis C- und HIV Infektionen bei Empfängern von Erythrozytenkonzentraten (Bundesanzeiger Nr. 63 vom 04.04.1997, S. 4477) Bundesanzeiger. 1989;53:3835.
    1. Albertia A, Caporaso N. HBV therapy: Guidelines and open issues. Dig Liver Dis. 2011;43(suppl 1):S57–63. - PubMed
    1. Zaaijer HL, Cuypers HT, Reesink HW, Winkel IN, Gerken G, Lelie PN. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet. 1993;341:722–724. - PubMed
    1. Damen M, Cuypers HT, Zaaijer HL, Reesink HW, Schaasberg WP, Gerlich WH, Niesters HG, Lelie PN. International collaborative study on the second EUROHEP HCV-RNA reference panel. J Virol Methods. 1996;58:175–185. - PubMed
    1. Saldanha J, Minor P. Collaborative study to assess the suitability of an HCV RNA reference sample for detection of an HCV RNA in plasma pools by PCR. Vox Sang. 1996;703:148–151. - PubMed

LinkOut - more resources